The FDA’s proposed competency-based approach reflects a fundamental shift in medical regulation: as AI systems begin performing tasks traditionally entrusted to clinicians, regulators may increasingly judge them by what they can reliably do rather than simply how their software was built. (Source: Image by RR)

FDA Considers Physician-Inspired Testing for AI Healthcare Systems

The U.S. Food and Drug Administration is exploring a fundamentally different way of evaluating medical devices powered by generative artificial intelligence: testing their clinical competency in a manner inspired by how human physicians are evaluated and credentialed. Rather than treating these systems solely like traditional medical equipment or software, the FDA is considering benchmarks that measure whether an AI system can reliably perform specific clinical tasks and demonstrate adequate performance in real-world healthcare environments.

The proposal, as noted in yahoo.com, reflects a growing regulatory challenge as generative AI enters increasingly consequential areas of medicine. Unlike conventional medical devices that generally perform predictable functions, generative AI systems can produce varying outputs, adapt over time and operate across a broad range of clinical scenarios. The FDA’s discussion paper therefore proposes assessing risk based both on the type of medical activity an AI performs and the potential consequences if its output is wrong, with higher-risk applications requiring correspondingly stronger evidence of safety and effectiveness.

The agency is also considering greater reliance on continuous monitoring after AI-enabled devices reach the market. Because generative systems can evolve and their performance may change across patient populations and clinical environments, traditional premarket approval may provide only a partial picture of their long-term safety. One possibility raised by the FDA is accepting somewhat greater uncertainty before approval while requiring significantly stronger postmarket surveillance to identify emerging problems and verify that systems continue performing as intended.

A crucial unresolved question is what level of performance medical AI should actually be required to achieve. The FDA suggests that some systems could potentially be compared against panels of qualified clinicians representing the standard of care, or against the performance of a median practicing physician. Although the discussion remains preliminary and does not constitute formal regulatory guidance, the approach could ultimately establish an important principle for medical AI: systems performing increasingly doctor-like tasks may eventually need to demonstrate doctor-like competence.

read more at yahoo.com